List view / Grid view
AstraZeneca plc is an Anglo–Swedish multinational pharmaceutical and biopharmaceutical company.
In 2013, it moved its headquarters to Cambridge, United Kingdom, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015, it was the eighth-largest drug company in the world based on sales revenue.
AstraZeneca has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the English Zeneca Group (itself formed by the demerger of the pharmaceutical operations of Imperial Chemical Industries in 1993). It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014).
1 October 2015 | By Victoria White
Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signalling...
11 September 2015 | By Victoria White
The facility will eventually double AstraZeneca’s biologics manufacturing capacity in the US to meet the needs of the Company’s maturing pipeline...
9 September 2015 | By Victoria White
Data demonstrated that in 60 patients who received AZD9291 once daily in the first-line setting, 72% were progression free at 12 months...
9 September 2015 | By Victoria White
AstraZeneca and The University of Manchester are teaming up to harness clinical bioinformatics to deliver personalised healthcare for cancer patients...
4 September 2015 | By Victoria White
The FDA has approved Brilinta tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year...
2 September 2015 | By Victoria White
Positive results from RECAPTURE 1 and 2, Phase III studies evaluating the antibiotic Avycaz as a treatment for patients with cUTI, have been announced...
24 August 2015 | By Victoria White
AstraZeneca and Peregrine Pharmaceuticals are to evaluate the safety and efficacy of Peregrine’s bavituximab in combination with AstraZeneca’s durvalumab...
11 August 2015 | By Katie Sadler, Digital Content Producer, European Pharmaceutical Review
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
31 July 2015 | By Victoria White
Roche submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the FDA, as a companion diagnostic test for AZD9291...
22 July 2015 | By Victoria White
A Phase III study of selumetinib in combination with dacarbazine for the treatment of metastatic uveal melanoma failed to meet its primary endpoint...
14 July 2015 | By Victoria White
The FDA has approved Iressa for the first-line treatment of patients with NSCLC whose tumours have EGFR exon 19 deletions or exon 21 substitution mutations...
9 July 2015 | By Victoria White
Tillotts Pharma has entered into an agreement for the acquisition of the global rights for Entocort from AstraZeneca, excluding the US...
15 June 2015 | By Victoria White
AstraZeneca presented results from its Phase III trial investigating lesinurad in combination with febuxostat in patients with tophaceous gout at EULAR 2015...
2 June 2015 | By Victoria White
Draft guidance issued by NICE on the drug olaparib do not recommend its use for maintenance treatment of ovarian, fallopian tube and peritoneal cancer...
1 June 2015 | By Victoria White
AstraZeneca has announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of EGFRm advanced non-small cell lung cancer (NSCLC)...
